中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2015年
6期
44-46
,共3页
缺血性卒中%化痰逐瘀汤%二级预防%应用价值
缺血性卒中%化痰逐瘀湯%二級預防%應用價值
결혈성졸중%화담축어탕%이급예방%응용개치
Ischemic stroke%Huatan Zhuyu decoction%Secondary prevention%Value
目的:探讨化痰逐瘀汤在缺血性卒中二级预防中的应用价值。方法随机将86例缺血性卒中患者分为A及B两组,每组43例。A组给予常规治疗,B组给予常规联合化痰逐瘀汤治疗,对两组二级预防效果进行对比。结果治疗前两组功能独立性评定量表(FIM)评分、甘油三酯(TG)、总胆固醇(TC)及低密度脂蛋白胆固醇(LDL-C)比较差异无统计学意义(P>0.05),但经治疗后B组FIM评分、TG、TC及LDL-C均较A组明显好转(P<0.05)。同时B组总有效率明显优于A组(P<0.05),且两组药物副作用发生率比较差异无统计学意义(P>0.05)。结论化痰逐瘀汤可有效提高缺血性卒中的二级预防效果。
目的:探討化痰逐瘀湯在缺血性卒中二級預防中的應用價值。方法隨機將86例缺血性卒中患者分為A及B兩組,每組43例。A組給予常規治療,B組給予常規聯閤化痰逐瘀湯治療,對兩組二級預防效果進行對比。結果治療前兩組功能獨立性評定量錶(FIM)評分、甘油三酯(TG)、總膽固醇(TC)及低密度脂蛋白膽固醇(LDL-C)比較差異無統計學意義(P>0.05),但經治療後B組FIM評分、TG、TC及LDL-C均較A組明顯好轉(P<0.05)。同時B組總有效率明顯優于A組(P<0.05),且兩組藥物副作用髮生率比較差異無統計學意義(P>0.05)。結論化痰逐瘀湯可有效提高缺血性卒中的二級預防效果。
목적:탐토화담축어탕재결혈성졸중이급예방중적응용개치。방법수궤장86례결혈성졸중환자분위A급B량조,매조43례。A조급여상규치료,B조급여상규연합화담축어탕치료,대량조이급예방효과진행대비。결과치료전량조공능독립성평정량표(FIM)평분、감유삼지(TG)、총담고순(TC)급저밀도지단백담고순(LDL-C)비교차이무통계학의의(P>0.05),단경치료후B조FIM평분、TG、TC급LDL-C균교A조명현호전(P<0.05)。동시B조총유효솔명현우우A조(P<0.05),차량조약물부작용발생솔비교차이무통계학의의(P>0.05)。결론화담축어탕가유효제고결혈성졸중적이급예방효과。
Objective To study the value of Huatan Zhuyu decoction on secondary prevention in patients with ischemic stroke. Methods 86 patients with ischemic stroke were randomly divided into A group and B group, with 43 cases in each group. To compare the effect of secondary prevention between A group who were treated with routine treatment and B group who were treated with Huatan Zhuyu decoction based on routine treatment. Results Functional independence measure scores(FIM), triglyceride(TG), total cholesterol(TC), and low density lipoprotein cholesterol(LDL-C) before treatment between the two groups had no statistical significance(P>0.05), but which after treatment in B group were obviously better than which in A group(P<0.05). The total effective rate in B group was obviously better than which in A group(P < 0.05), while the incidence rate of medicine side effect between the two groups had no statistical significance(P > 0.05). Conclusion Huatan Zhuyu decoction could improve the clinical effect of secondary prevention in patients with ischemic stroke.